Nov. 21 at 6:52 PM
In the 4 weeks since
$BIIB announced “up to”
$1.1b in pre clinical C5aR inhibitor Vanqua, it’s added
$35 / share
of value.
With 145m shares outstanding, it’s added
$4.5b in 4 weeks since beefing up their CNS / Alzheimer’s/ under disguise of building “I&I” biz.
Wonder if anyone else can match this shareholder ROI
The only other public 100% focused C5aR entity being
$100M valued
$IFRX. It won’t stay independent very much longer.
Avacopan another gem for
$AMGN aside from liver tox.
Will it be Amgen to “right a wrong” or
$ABBV $RHHBY to pipeline (a verb)?
